

Discovery and validation of vascular endothelial growth factor polymorphisms in esophageal adenocarcinoma outcomes

Carcinogenesis

36, 956-962

DOI: [10.1093/carcin/bgv073](https://doi.org/10.1093/carcin/bgv073)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. <i>Pharmacological Research</i> , 2016, 111, 290-302.	3.1	156
2	Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival. <i>Cancer Medicine</i> , 2017, 6, 361-373.	1.3	11
3	Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population. <i>Oncotarget</i> , 2017, 8, 16488-16497.	0.8	10
4	Esophageal cancer: Risk factors, genetic association, and treatment. <i>Asian Journal of Surgery</i> , 2018, 41, 210-215.	0.2	510
5	A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas. <i>Scientific Reports</i> , 2018, 8, 13281.	1.6	28
6	Identifying potential metastasis-related long non-coding RNAs, microRNAs, and message RNAs in the esophageal squamous cell carcinoma. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 13202-13215.	1.2	15